A Case of Idiopathic Retinitis Vasculitis Aneurysms and Neuroretinitis (IRVAN) Treated with Adalimumab

Ocul Immunol Inflamm. 2023 Apr;31(3):627-630. doi: 10.1080/09273948.2022.2039209. Epub 2022 Mar 22.

Abstract

Purpose: To report a case of IRVAN in a 13-year-old girl responding well to Adalimumab and Azathioprine.

Results: A 13-year-old girl presented to us with central scotoma for a duration of 10 months. She was treated earlier with oral steroids with poor response. Fundus examination revealed features of IRVAN. She was treated with intravitreal dexamethasone implant in both eyes with oral Mycophenolate Mofetil (MMF) with transient response to it. So she was switched over to subcutaneous Adalimumab 40 mg once in 2 weeks and oral Azathioprine 50 mg BD. The disease activity was well controlled with the current regime.

Conclusion: Though various treatment modalities have been described in literature for the treatment of IRVAN. This is the first case of IRVAN to be treated with Adalimumab along with Azathioprine to be reported.

Keywords: Adalimumab; Aneurysmal dilatation; IRVAN; Neuroretinitis; Vasculitis.

Publication types

  • Case Reports

MeSH terms

  • Adalimumab / therapeutic use
  • Adolescent
  • Aneurysm* / diagnosis
  • Aneurysm* / drug therapy
  • Azathioprine / therapeutic use
  • Chorioretinitis*
  • Female
  • Fluorescein Angiography
  • Humans
  • Retinal Vasculitis* / diagnosis
  • Retinal Vasculitis* / drug therapy
  • Retinitis* / diagnosis
  • Retinitis* / drug therapy

Substances

  • Adalimumab
  • Azathioprine